ArticleResearch square2025
Efficacy of 5×5 accelerated versus conventional repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
18 authors.
Funding
Abstract
Accelerated repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for Major Depressive Disorder (MDD), with an FDA-cleared protocol utilizing 10 sessions of prolonged intermittent Theta Burst Stimulation (piTBS) per day for five days. However, it remains unclear how many sessions and pulses are necessary to achieve benefit. We examined efficacy of five stimulation sessions per day for five days ("5×5") of either piTBS or individualized, electroencephalogram-based "resonant frequency" (RF) stimulation. We compared MDD symptom improvement (PHQ-9) between two groups: 1) accelerated patients (N = 40) undergoing 5×5 treatment (patients received piTBS or RF rTMS) and 2) conventional patients (N = 135) receiving standard once daily rTMS. Both protocols ameliorated MDD symptoms and there were no statistically significant differences in depression symptom changes (p = .07) between the accelerated 5×5 protocol (mean PHQ-9: pre-rTMS = 17.68, post-rTMS = 10.98) and conventional once-daily treatment (mean PHQ-9: pre-rTMS = 17.83, post-rTMS = 8.97). There was no significant difference in improvement between the piTBS and RF 5×5 protocols (p = 0.9). A PHQ-9 median split of 5×5 patients revealed that the top half of patients showed robust depression improvement (69%) while the bottom half received no significant benefit (8%) by day 5. However, the bottom half showed significant improvement (36%) at two-to-four-week follow up (p = 0.001). These results suggest 5×5 accelerated rTMS treatment is as effective as once daily rTMS treatment and that the efficacy of accelerated treatment may not be accurately assessed until weeks after treatment completion.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.